 | • レポートコード：MRC2Q12-16840 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、反復拡張障害治療剤のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 反復拡張障害治療剤のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 反復拡張障害治療剤の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 反復拡張障害治療剤のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの反復拡張障害治療剤の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の反復拡張障害治療剤の売上および2028年までの予測に焦点を当てています。 反復拡張障害治療剤のグローバル主要企業には、Pfizer, Inc.、CRISPR Therapeutics、Acorda Therapeutics、Capsida Biotherapeutics Inc.、Larimar Therapeutics, Inc.、Healx, Intellia Therapeutics, Inc.、Editas Medicine、Bluebird bio, Inc.、Sanofi, Merck & Co., Inc.、H. Lundbeck A/S、Cellectis SA、Bio-Techne、GlaxoSmithKline plc、Allergan Aurobindo Pharma Ltd.、Sun Pharmaceutical Industries Ltd.、Torrent Pharmaceuticals Ltd.、Intas Pharmaceuticals Ltd.、Cipla Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 反復拡張障害治療剤市場は、タイプとアプリケーションによって区分されます。世界の反復拡張障害治療剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 経口、注射 【アプリケーション別セグメント】 病院薬局、小売店薬局、オンライン薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 反復拡張障害治療剤製品概要 - タイプ別市場（経口、注射） - アプリケーション別市場（病院薬局、小売店薬局、オンライン薬局） - 調査の目的 ・エグゼクティブサマリー - 世界の反復拡張障害治療剤販売量予測2017-2028 - 世界の反復拡張障害治療剤売上予測2017-2028 - 反復拡張障害治療剤の地域別販売量 - 反復拡張障害治療剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別反復拡張障害治療剤販売量 - 主要メーカー別反復拡張障害治療剤売上 - 主要メーカー別反復拡張障害治療剤価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（経口、注射） - 反復拡張障害治療剤のタイプ別販売量 - 反復拡張障害治療剤のタイプ別売上 - 反復拡張障害治療剤のタイプ別価格 ・アプリケーション別市場規模（病院薬局、小売店薬局、オンライン薬局） - 反復拡張障害治療剤のアプリケーション別販売量 - 反復拡張障害治療剤のアプリケーション別売上 - 反復拡張障害治療剤のアプリケーション別価格 ・北米市場 - 北米の反復拡張障害治療剤市場規模（タイプ別、アプリケーション別） - 主要国別の反復拡張障害治療剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの反復拡張障害治療剤市場規模（タイプ別、アプリケーション別） - 主要国別の反復拡張障害治療剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の反復拡張障害治療剤市場規模（タイプ別、アプリケーション別） - 主要国別の反復拡張障害治療剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の反復拡張障害治療剤市場規模（タイプ別、アプリケーション別） - 主要国別の反復拡張障害治療剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの反復拡張障害治療剤市場規模（タイプ別、アプリケーション別） - 主要国別の反復拡張障害治療剤市場規模（トルコ、サウジアラビア） ・企業情報 Pfizer, Inc.、CRISPR Therapeutics、Acorda Therapeutics、Capsida Biotherapeutics Inc.、Larimar Therapeutics, Inc.、Healx, Intellia Therapeutics, Inc.、Editas Medicine、Bluebird bio, Inc.、Sanofi, Merck & Co., Inc.、H. Lundbeck A/S、Cellectis SA、Bio-Techne、GlaxoSmithKline plc、Allergan Aurobindo Pharma Ltd.、Sun Pharmaceutical Industries Ltd.、Torrent Pharmaceuticals Ltd.、Intas Pharmaceuticals Ltd.、Cipla Ltd ・産業チェーン及び販売チャネル分析 - 反復拡張障害治療剤の産業チェーン分析 - 反復拡張障害治療剤の原材料 - 反復拡張障害治療剤の生産プロセス - 反復拡張障害治療剤の販売及びマーケティング - 反復拡張障害治療剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 反復拡張障害治療剤の産業動向 - 反復拡張障害治療剤のマーケットドライバー - 反復拡張障害治療剤の課題 - 反復拡張障害治療剤の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Repeat Expansion Disorders Treatment estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Repeat Expansion Disorders Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Repeat Expansion Disorders Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Repeat Expansion Disorders Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Repeat Expansion Disorders Treatment include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, Bluebird bio, Inc. and Sanofi, Merck & Co., Inc., etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Repeat Expansion Disorders Treatment companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Repeat Expansion Disorders Treatment market. Further, it explains the major drivers and regional dynamics of the global Repeat Expansion Disorders Treatment market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Pfizer, Inc.
CRISPR Therapeutics
Acorda Therapeutics
Capsida Biotherapeutics Inc.
Larimar Therapeutics, Inc.
Healx, Intellia Therapeutics, Inc.
Editas Medicine
Bluebird bio, Inc.
Sanofi, Merck & Co., Inc.
H. Lundbeck A/S
Cellectis SA
Bio-Techne
GlaxoSmithKline plc
Allergan Aurobindo Pharma Ltd.
Sun Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Intas Pharmaceuticals Ltd.
Cipla Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Repeat Expansion Disorders Treatment Segment by Type
Oral
Injection
Repeat Expansion Disorders Treatment Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Repeat Expansion Disorders Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Repeat Expansion Disorders Treatment market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Repeat Expansion Disorders Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Repeat Expansion Disorders Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Repeat Expansion Disorders Treatment revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Repeat Expansion Disorders Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Repeat Expansion Disorders Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, Bluebird bio, Inc. and Sanofi, Merck & Co., Inc., etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Repeat Expansion Disorders Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Repeat Expansion Disorders Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Repeat Expansion Disorders Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Repeat Expansion Disorders Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Repeat Expansion Disorders Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Repeat Expansion Disorders Treatment Market Perspective (2017-2028)
2.2 Repeat Expansion Disorders Treatment Growth Trends by Region
2.2.1 Repeat Expansion Disorders Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Repeat Expansion Disorders Treatment Historic Market Size by Region (2017-2022)
2.2.3 Repeat Expansion Disorders Treatment Forecasted Market Size by Region (2023-2028)
2.3 Repeat Expansion Disorders Treatment Market Dynamics
2.3.1 Repeat Expansion Disorders Treatment Industry Trends
2.3.2 Repeat Expansion Disorders Treatment Market Drivers
2.3.3 Repeat Expansion Disorders Treatment Market Challenges
2.3.4 Repeat Expansion Disorders Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Repeat Expansion Disorders Treatment Players by Revenue
3.1.1 Global Top Repeat Expansion Disorders Treatment Players by Revenue (2017-2022)
3.1.2 Global Repeat Expansion Disorders Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Repeat Expansion Disorders Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Repeat Expansion Disorders Treatment Revenue
3.4 Global Repeat Expansion Disorders Treatment Market Concentration Ratio
3.4.1 Global Repeat Expansion Disorders Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Repeat Expansion Disorders Treatment Revenue in 2021
3.5 Repeat Expansion Disorders Treatment Key Players Head office and Area Served
3.6 Key Players Repeat Expansion Disorders Treatment Product Solution and Service
3.7 Date of Enter into Repeat Expansion Disorders Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Repeat Expansion Disorders Treatment Breakdown Data by Type
4.1 Global Repeat Expansion Disorders Treatment Historic Market Size by Type (2017-2022)
4.2 Global Repeat Expansion Disorders Treatment Forecasted Market Size by Type (2023-2028)
5 Repeat Expansion Disorders Treatment Breakdown Data by Application
5.1 Global Repeat Expansion Disorders Treatment Historic Market Size by Application (2017-2022)
5.2 Global Repeat Expansion Disorders Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Repeat Expansion Disorders Treatment Market Size (2017-2028)
6.2 North America Repeat Expansion Disorders Treatment Market Size by Type
6.2.1 North America Repeat Expansion Disorders Treatment Market Size by Type (2017-2022)
6.2.2 North America Repeat Expansion Disorders Treatment Market Size by Type (2023-2028)
6.2.3 North America Repeat Expansion Disorders Treatment Market Share by Type (2017-2028)
6.3 North America Repeat Expansion Disorders Treatment Market Size by Application
6.3.1 North America Repeat Expansion Disorders Treatment Market Size by Application (2017-2022)
6.3.2 North America Repeat Expansion Disorders Treatment Market Size by Application (2023-2028)
6.3.3 North America Repeat Expansion Disorders Treatment Market Share by Application (2017-2028)
6.4 North America Repeat Expansion Disorders Treatment Market Size by Country
6.4.1 North America Repeat Expansion Disorders Treatment Market Size by Country (2017-2022)
6.4.2 North America Repeat Expansion Disorders Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Repeat Expansion Disorders Treatment Market Size (2017-2028)
7.2 Europe Repeat Expansion Disorders Treatment Market Size by Type
7.2.1 Europe Repeat Expansion Disorders Treatment Market Size by Type (2017-2022)
7.2.2 Europe Repeat Expansion Disorders Treatment Market Size by Type (2023-2028)
7.2.3 Europe Repeat Expansion Disorders Treatment Market Share by Type (2017-2028)
7.3 Europe Repeat Expansion Disorders Treatment Market Size by Application
7.3.1 Europe Repeat Expansion Disorders Treatment Market Size by Application (2017-2022)
7.3.2 Europe Repeat Expansion Disorders Treatment Market Size by Application (2023-2028)
7.3.3 Europe Repeat Expansion Disorders Treatment Market Share by Application (2017-2028)
7.4 Europe Repeat Expansion Disorders Treatment Market Size by Country
7.4.1 Europe Repeat Expansion Disorders Treatment Market Size by Country (2017-2022)
7.4.2 Europe Repeat Expansion Disorders Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Repeat Expansion Disorders Treatment Market Size (2017-2028)
8.2 Asia-Pacific Repeat Expansion Disorders Treatment Market Size by Type
8.2.1 Asia-Pacific Repeat Expansion Disorders Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Repeat Expansion Disorders Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Repeat Expansion Disorders Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Repeat Expansion Disorders Treatment Market Size by Application
8.3.1 Asia-Pacific Repeat Expansion Disorders Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Repeat Expansion Disorders Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Repeat Expansion Disorders Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Repeat Expansion Disorders Treatment Market Size by Region
8.4.1 Asia-Pacific Repeat Expansion Disorders Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Repeat Expansion Disorders Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Repeat Expansion Disorders Treatment Market Size (2017-2028)
9.2 Latin America Repeat Expansion Disorders Treatment Market Size by Type
9.2.1 Latin America Repeat Expansion Disorders Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Repeat Expansion Disorders Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Repeat Expansion Disorders Treatment Market Share by Type (2017-2028)
9.3 Latin America Repeat Expansion Disorders Treatment Market Size by Application
9.3.1 Latin America Repeat Expansion Disorders Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Repeat Expansion Disorders Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Repeat Expansion Disorders Treatment Market Share by Application (2017-2028)
9.4 Latin America Repeat Expansion Disorders Treatment Market Size by Country
9.4.1 Latin America Repeat Expansion Disorders Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Repeat Expansion Disorders Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Repeat Expansion Disorders Treatment Market Size (2017-2028)
10.2 Middle East & Africa Repeat Expansion Disorders Treatment Market Size by Type
10.2.1 Middle East & Africa Repeat Expansion Disorders Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Repeat Expansion Disorders Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Repeat Expansion Disorders Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Repeat Expansion Disorders Treatment Market Size by Application
10.3.1 Middle East & Africa Repeat Expansion Disorders Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Repeat Expansion Disorders Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Repeat Expansion Disorders Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Repeat Expansion Disorders Treatment Market Size by Country
10.4.1 Middle East & Africa Repeat Expansion Disorders Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Repeat Expansion Disorders Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Details
11.1.2 Pfizer, Inc. Business Overview
11.1.3 Pfizer, Inc. Repeat Expansion Disorders Treatment Introduction
11.1.4 Pfizer, Inc. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.1.5 Pfizer, Inc. Recent Developments
11.2 CRISPR Therapeutics
11.2.1 CRISPR Therapeutics Company Details
11.2.2 CRISPR Therapeutics Business Overview
11.2.3 CRISPR Therapeutics Repeat Expansion Disorders Treatment Introduction
11.2.4 CRISPR Therapeutics Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.2.5 CRISPR Therapeutics Recent Developments
11.3 Acorda Therapeutics
11.3.1 Acorda Therapeutics Company Details
11.3.2 Acorda Therapeutics Business Overview
11.3.3 Acorda Therapeutics Repeat Expansion Disorders Treatment Introduction
11.3.4 Acorda Therapeutics Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.3.5 Acorda Therapeutics Recent Developments
11.4 Capsida Biotherapeutics Inc.
11.4.1 Capsida Biotherapeutics Inc. Company Details
11.4.2 Capsida Biotherapeutics Inc. Business Overview
11.4.3 Capsida Biotherapeutics Inc. Repeat Expansion Disorders Treatment Introduction
11.4.4 Capsida Biotherapeutics Inc. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.4.5 Capsida Biotherapeutics Inc. Recent Developments
11.5 Larimar Therapeutics, Inc.
11.5.1 Larimar Therapeutics, Inc. Company Details
11.5.2 Larimar Therapeutics, Inc. Business Overview
11.5.3 Larimar Therapeutics, Inc. Repeat Expansion Disorders Treatment Introduction
11.5.4 Larimar Therapeutics, Inc. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.5.5 Larimar Therapeutics, Inc. Recent Developments
11.6 Healx, Intellia Therapeutics, Inc.
11.6.1 Healx, Intellia Therapeutics, Inc. Company Details
11.6.2 Healx, Intellia Therapeutics, Inc. Business Overview
11.6.3 Healx, Intellia Therapeutics, Inc. Repeat Expansion Disorders Treatment Introduction
11.6.4 Healx, Intellia Therapeutics, Inc. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.6.5 Healx, Intellia Therapeutics, Inc. Recent Developments
11.7 Editas Medicine
11.7.1 Editas Medicine Company Details
11.7.2 Editas Medicine Business Overview
11.7.3 Editas Medicine Repeat Expansion Disorders Treatment Introduction
11.7.4 Editas Medicine Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.7.5 Editas Medicine Recent Developments
11.8 Bluebird bio, Inc.
11.8.1 Bluebird bio, Inc. Company Details
11.8.2 Bluebird bio, Inc. Business Overview
11.8.3 Bluebird bio, Inc. Repeat Expansion Disorders Treatment Introduction
11.8.4 Bluebird bio, Inc. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.8.5 Bluebird bio, Inc. Recent Developments
11.9 Sanofi, Merck & Co., Inc.
11.9.1 Sanofi, Merck & Co., Inc. Company Details
11.9.2 Sanofi, Merck & Co., Inc. Business Overview
11.9.3 Sanofi, Merck & Co., Inc. Repeat Expansion Disorders Treatment Introduction
11.9.4 Sanofi, Merck & Co., Inc. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.9.5 Sanofi, Merck & Co., Inc. Recent Developments
11.10 H. Lundbeck A/S
11.10.1 H. Lundbeck A/S Company Details
11.10.2 H. Lundbeck A/S Business Overview
11.10.3 H. Lundbeck A/S Repeat Expansion Disorders Treatment Introduction
11.10.4 H. Lundbeck A/S Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.10.5 H. Lundbeck A/S Recent Developments
11.11 Cellectis SA
11.11.1 Cellectis SA Company Details
11.11.2 Cellectis SA Business Overview
11.11.3 Cellectis SA Repeat Expansion Disorders Treatment Introduction
11.11.4 Cellectis SA Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.11.5 Cellectis SA Recent Developments
11.12 Bio-Techne
11.12.1 Bio-Techne Company Details
11.12.2 Bio-Techne Business Overview
11.12.3 Bio-Techne Repeat Expansion Disorders Treatment Introduction
11.12.4 Bio-Techne Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.12.5 Bio-Techne Recent Developments
11.13 GlaxoSmithKline plc
11.13.1 GlaxoSmithKline plc Company Details
11.13.2 GlaxoSmithKline plc Business Overview
11.13.3 GlaxoSmithKline plc Repeat Expansion Disorders Treatment Introduction
11.13.4 GlaxoSmithKline plc Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.13.5 GlaxoSmithKline plc Recent Developments
11.14 Allergan Aurobindo Pharma Ltd.
11.14.1 Allergan Aurobindo Pharma Ltd. Company Details
11.14.2 Allergan Aurobindo Pharma Ltd. Business Overview
11.14.3 Allergan Aurobindo Pharma Ltd. Repeat Expansion Disorders Treatment Introduction
11.14.4 Allergan Aurobindo Pharma Ltd. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.14.5 Allergan Aurobindo Pharma Ltd. Recent Developments
11.15 Sun Pharmaceutical Industries Ltd.
11.15.1 Sun Pharmaceutical Industries Ltd. Company Details
11.15.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.15.3 Sun Pharmaceutical Industries Ltd. Repeat Expansion Disorders Treatment Introduction
11.15.4 Sun Pharmaceutical Industries Ltd. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.15.5 Sun Pharmaceutical Industries Ltd. Recent Developments
11.16 Torrent Pharmaceuticals Ltd.
11.16.1 Torrent Pharmaceuticals Ltd. Company Details
11.16.2 Torrent Pharmaceuticals Ltd. Business Overview
11.16.3 Torrent Pharmaceuticals Ltd. Repeat Expansion Disorders Treatment Introduction
11.16.4 Torrent Pharmaceuticals Ltd. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.16.5 Torrent Pharmaceuticals Ltd. Recent Developments
11.17 Intas Pharmaceuticals Ltd.
11.17.1 Intas Pharmaceuticals Ltd. Company Details
11.17.2 Intas Pharmaceuticals Ltd. Business Overview
11.17.3 Intas Pharmaceuticals Ltd. Repeat Expansion Disorders Treatment Introduction
11.17.4 Intas Pharmaceuticals Ltd. Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.17.5 Intas Pharmaceuticals Ltd. Recent Developments
11.18 Cipla Ltd
11.18.1 Cipla Ltd Company Details
11.18.2 Cipla Ltd Business Overview
11.18.3 Cipla Ltd Repeat Expansion Disorders Treatment Introduction
11.18.4 Cipla Ltd Revenue in Repeat Expansion Disorders Treatment Business (2017-2022)
11.18.5 Cipla Ltd Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer